Axsome Therapeutics (MIL:1AXSM) Inventories, Other: €32.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1AXSM Axsome Therapeutics Inc MIL:1AXSM
13 GF Score
Price €184.75
GF Value €193.37
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Axsome Therapeutics Inventories, Other?

Axsome Therapeutics MIL:1AXSM 13 Inventories, Other is €32.9 Mil as of Jun. 2026. GuruFocus rates MIL:1AXSM with a GF Score™ of 13/100 and a GF Value™ of €193.37 (Fairly Valued). The stock has 1 warning sign investors should review.

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Axsome Therapeutics's other inventories for the quarter that ended in Jun. 2026 was €32.9 Mil.

Axsome Therapeutics's quarterly other inventories increased from Dec. 2025 (€23.9 Mil) to Mar. 2026 (€27.3 Mil) and increased from Mar. 2026 (€27.3 Mil) to Jun. 2026 (€32.9 Mil).

Axsome Therapeutics's annual other inventories increased from Dec. 2023 (€13.9 Mil) to Dec. 2024 (€15.0 Mil) and increased from Dec. 2024 (€15.0 Mil) to Dec. 2025 (€23.9 Mil).

Axsome Therapeutics Inventories, Other Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Inventories, Other Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.08 13.88 15.02 23.86

Axsome Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.99 20.26 23.86 27.26 32.88
MIL:1AXSM
13GF Score
Axsome Therapeutics Inc MIL:1AXSM
Inventories, Other is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Frequently Asked Questions Learn more about Inventories, Other →
What does a Inventories, Other of €32.9 Mil mean?
Axsome Therapeutics (MIL:1AXSM) has a Inventories, Other of €32.9 Mil as of Jun. 2026. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Inventories, Other too high?
Axsome Therapeutics' current Inventories, Other is €32.9 Mil. Overall, Axsome Therapeutics has a GF Score™ of 13/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Inventories, Other compare to KRYS and APGE?
Axsome Therapeutics' Inventories, Other of €32.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Other for a Biotechnology company?
A good Inventories, Other depends on the Biotechnology industry context. However, Inventories, Other should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Other mean?
A high Inventories, Other can signal that a stock is expensive relative to its fundamentals. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Inventories, Other is €32.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (MIL:1AXSM) is currently considered Fairly Valued. The stock's GF Value™ is €193.37, compared to a current price of €184.75 — trading 4.5% below its estimated fair value. The current Inventories, Other is €32.9 Mil. Axsome Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Other calculated?
Inventories, Other is calculated from a company's financial statements. For Axsome Therapeutics (MIL:1AXSM), the current Inventories, Other is €32.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (MIL:1AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be undervalued. The current stock price of €184.75 is trading 4.5% below its estimated GF Value™ of €193.37. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for MIL:1AXSM:

  • Inventories, Other: €32.9 Mil
  • GF Value™: €193.37 vs. price of €184.75 (4.5% below fair value)
  • GF Score™: 13/100 with 1 warning sign

No single metric tells the full story. See the MIL:1AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Other Exchanges AXSM:USA0HKF:UK19X:Germany
Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
13GF Score

Get the complete analysis for MIL:1AXSM

Inventories, Other is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€184.75
Price
€193.37
GF Value